ArticleRadiation protection dosimetry2026
Modelling the relative precision of whole-kidney dosimetry in molecular radiotherapy using a power law approach.
Article in Radiation protection dosimetry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A power-law model was introduced to characterize the relationship between spherical volumes-of-interest (SVs) and whole kidney parenchyma (WKP)-derived absorbed dose estimates, enabling quantitative precision for image-based dosimetry. Single photon emission computed tomography/computed tomography (SPECT/CT) images were acquired at 24, 48, and 168 h after [177Lu]Lu-DOTATATE treatment in 18 patients. Kidney activity was quantified using WKP and SV-based methods (2 and 0.6 ml) on SPECT-images. WKP and both SV approaches showed good agreement in kidney dosimetry, with normalization factors of 1.12 and 1.23 (standard error mean ≤1.2%), and improved precision when multiple SVs were used. The power-law model demonstrated excellent fit (R2 > 0.97) and high precision (~7%), with no significant difference between SV sizes (P = .15) and minimal bias (<0.003%). This power law model presents a novel method for quantifying the relative precision of SPECT-derived kidney dosimetry. Further validation is warranted to address residual uncertainty and complex noise correlation in the SV-based dose estimates.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.